Ballentine Partners’s Bio-Rad Laboratories Class A BIO Stock Holding History

Ballentine Partners’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-714	Closed	-$235K	–	918
2024 Q4	$235K	Buy	714 +35	+5%	+$11.9K	﹤0.01%	715
2024 Q3	$227K	Buy	+679	New	+$216K	﹤0.01%	703
2024 Q2	–	Sell	-615	Closed	-$213K	–	762
2024 Q1	$213K	Buy	+615	New	+$202K	﹤0.01%	653

Other funds holding BIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Ballentine Partners's BIO Position: Q1 2025 in Review

Ballentine Partners sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2025, closing a stake of 714 shares — an estimated $235K sold.

Ballentine Partners first reported a position in BIO in Q1 2024 and held it in 3 quarters. The position peaked at $235K in Q4 2024. 437 funds tracked by Wall St. Rank hold BIO as of Q1 2025.

Ballentine Partners reported no remaining Bio-Rad Laboratories Class A position as of Q1 2025 after selling out during the quarter.
Ballentine Partners sold 714 Bio-Rad Laboratories Class A shares in Q1 2025, an estimated $235K.
Ballentine Partners first reported a position in Bio-Rad Laboratories Class A in Q1 2024 and held it in 3 quarters.
Ballentine Partners's Bio-Rad Laboratories Class A position peaked at $235K in Q4 2024.
437 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2025.

Based on Ballentine Partners's 13F filing for Q1 2025, filed 1 May 2025.